Key facts
- Notable investors include SOSV, IndieBio.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Asta Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Asta Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Asta Bio
Developer of radiotherapeutics intended for cancer patients. The company offers technology to combine 211-Astatine, the druggable alpha-emitting radioisotope, with multivalent single-domain antibodies to deliver potent alpha radiation particles, enabling healthcare providers to break DNA strands and kill the tumor cells while leaving normal cells unaffected.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 3
- Website
- astabiotx.com/
- Ownership
- Privately Held (backing)
Asta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Asta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Asta Bio in its N-PORT filings yet. We sweep new filings monthly.